


Data Sheet

WWW.UREIKO-CHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :RMC-6291
Cat.No. :URK-V2531
CAS No. :2641998-63-0
Molecular Weight :1012.26
Molecular Formula :C₅₅H₇₈FN₉O₈
Target :
Solubility :



Biological Activity

RMC-6291 is a promising small-molecule inhibitor that has recently gained significant attention in the field of cancer research. It is a potent and selective inhibitor of the protein kinases PIM1 and PIM2, two important targets in the treatment of cancer.

RMC-6291 has a strong anti-cancer effect on different types of cancer cells, including leukemia, prostate, lung, and breast cancer cells. The compound inhibits cancer cell growth and induces apoptosis by disrupting the downstream signaling pathways of PIM kinases.

RMC-6291 has good pharmacokinetic properties, low toxicity, and high efficacy in animal models.

RMC-6291 exhibits synergistic effects with other chemotherapeutic agents, making it a potential candidate for combination therapy.

References

1. Wang Z, et al. Discovery, structure-activity relationships, and biological evaluation of non-peptidic Pim inhibitors. *Bioorg Med Chem Lett*. 2015 Jul 1; 25(13): 2615-21.
2. Kelly KR, et al. First-in-Human Study of the Pim Kinase Inhibitor, RMC-4630 (RMC-5552 / R-763), as Monotherapy in Patients with Advanced Relapsed/Refractory Solid Tumors or NHL: Overall Safety and Efficacy. *J Clin Oncol*. 2019 May 20; 37(15_suppl): 2513-2513.
3. Mishra R, et al. PIM kinase inhibitor, RMC-4630 exhibits potent anti-tumor activity in AML. *Cancer Res*. 2018 Dec 15; 78(24 Suppl):Abstract nr 2766.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only!

JACK@UREIKO-CHEM.COM